• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Anzalone Christopher Richard sold $5,274,334 worth of shares (300,000 units at $17.58) and exercised 300,000 shares at a strike of $7.75 (SEC Form 4)

    3/5/25 6:32:06 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Anzalone Christopher Richard

    (Last) (First) (Middle)
    177 E. COLORADO BLVD
    SUITE 700

    (Street)
    PASADENA CA 91105

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/03/2025 M 166,667 A $7.75 3,940,469 D
    Common Stock 03/04/2025 M 133,333 A $7.75 4,073,802 D
    Common Stock 03/03/2025 S(1) 166,667 D $18.03 3,907,135 D
    Common Stock 03/04/2025 S(1) 133,333 D $17.02(2) 3,773,802 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy Common Stock) $7.75 03/03/2025 M 166,667 03/06/2015(3) 03/06/2025 Common Stock 166,667 $0 185,059 D
    Stock Option (right to buy Common Stock) $7.75 03/03/2025 M 133,333 03/06/2015(3) 03/06/2025 Common Stock 133,333 $0 51,726 D
    Explanation of Responses:
    1. The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
    2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.58 to $ 17.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
    3. All options were fully vested and exercisable as of March 6, 2015.
    Remarks:
    /s/Christopher Anzalone 03/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARWR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARWR

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    More analyst ratings

    $ARWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

      SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      11/14/24 9:38:25 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      10/16/24 9:15:20 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      4/10/24 2:03:52 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using

      5/7/25 7:30:00 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

      4/30/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    SEC Filings

    See more
    • Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      4/15/25 3:50:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by Arrowhead Pharmaceuticals Inc.

      424B7 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      3/7/25 4:15:52 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by Arrowhead Pharmaceuticals Inc.

      SCHEDULE 13D - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      2/14/25 5:23:17 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Financials

    Live finance-specific insights

    See more
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

      4/30/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

      - Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for

      2/10/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will

      1/22/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/20/24 7:06:58 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      4/11/25 6:20:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard was granted 340,000 shares and sold $774,975 worth of shares (51,425 units at $15.07), increasing direct ownership by 8% to 4,062,377 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/17/25 5:45:33 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard sold $5,274,334 worth of shares (300,000 units at $17.58) and exercised 300,000 shares at a strike of $7.75 (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/5/25 6:32:06 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Leadership Updates

    Live Leadership Updates

    See more

    $ARWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

      NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

      1/22/25 5:54:00 PM ET
      $APO
      $ARWR
      $B
      $GWRE
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Goldman initiated coverage on Arrowhead with a new price target

      Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

      6/5/24 7:11:50 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Arrowhead with a new price target

      BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00

      12/4/23 7:19:37 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Arrowhead with a new price target

      Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00

      9/19/23 7:26:13 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care